Lumicks USA Inc.

Lumicks USA Inc., a foreign-owned for-profit organization, supplies specialized single-molecule research instruments and related services to the National Institutes of Health as a prime contractor, operating exclusively outside small-business set-asides on full-and-open federal procurements. Lumicks is based in Morrisville, North Carolina, with a secondary facility in Waltham, Massachusetts, and operates across analytical laboratory instrument manufacturing (NAICS 541380) and laboratory equipment maintenance and repair services (PSC codes 4220 and 4235).

Lumicks' federal footprint concentrates entirely within the Department of Health and Human Services National Institutes of Health component institutes, which account for 100% of eight prime awards totaling $2.1 million in combined potential value. The National Heart Lung and Blood Institute leads by dollar value ($1 million across two awards), followed by the National Institute of Environmental Health Sciences ($940 thousand across two awards). The National Cancer Institute, the National Institute of Biomedical Imaging and Bioengineering, and the National Institute of Neurological Disorders and Stroke round out the active customer set. Recent representative work includes a $996,710 firm fixed-price purchase order from the National Heart Lung and Blood Institute (August 2023) for generation of transgenic and knock-in mouse models using CRISPR/Cas9 genome editing technology; a $756,600 purchase order from the National Institute of Environmental Health Sciences (September 2025) for a Dymo200 C-trap optical tweezers system for the Structural Biology Core facility supporting single-molecule research; a $183,100 purchase order from the National Institute of Environmental Health Sciences (September 2026) to upgrade an existing C-trap instrument from 2-color to 3-color confocal fluorescence capability with laser installation and warranty extension through February 2029; and a $74,900 purchase order from the National Institute of Biomedical Imaging and Bioengineering (September 2026) for a C-TRAP Dymo 400 optical tweezers system with performance at Bethesda, Maryland.

Lumicks has no parent IDIQs, GWACs, or agency-wide vehicles in the source data and operates solely as a prime contractor on purchase-order awards issued through standard commercial-items procedures (FAR 12.603). Activity remains sparse — three awards in 2022, then one per year through 2025, and two in 2026. Two awards (combined potential value $258 thousand) reach ultimate completion within the next twenty-four months and face recompete exposure. Lumicks conducts no subcontract work and maintains no named teaming relationships in the source.